Head-to-head evidence
Olaparib vs Talazoparib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: PARP · full HR+/HER2- Metastatic Breast Cancer pipeline
Olaparib
Marketed by AstraZeneca and partners
NCT02000622 · Phase 3 · completed
The trial randomly assigned 302 participants to olaparib or active chemotherapy, but treatment was open-label rather than double-blinded. The hard clinical primary endpoint, independently reviewed progression-free survival, was met: median PFS was 7.0 versus 4.2 months, with a hazard ratio of 0.58 (95% CI 0.43–0.80; p=0.0009).
Next expected readout: March 2027 · NCT07113964 (registry estimate)
Talazoparib
Marketed by Pfizer and partners
NCT01945775 · Phase 3 · completed
Participants were randomized 2:1 to talazoparib or physician’s-choice chemotherapy, with 287 and 144 participants respectively, but treatment assignment was not blinded. The primary radiologic progression-free survival endpoint was met, with a statistically significant benefit for talazoparib; the open-label design and nonsignificant overall-survival result support a moderate evidence grade.
Next expected readout: January 2027 · NCT04039230 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Olaparib's landscape · Talazoparib's landscape